MARKET WIRETradingView • 15h ago
ANIK Q3'26 Earnings: revenue estimate is 29.44M USDTradingView report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
Why ANIK Stock dropped -3.85% Today — RQD Quant Desk Flash
$20.95 -3.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $20.77
Anika Therapeutics Inc. (ANIK) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $280.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ANIK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $20.95 (-3.85% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #236 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ANIK compare to INFU and TMCI in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ANIK?
▼
Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $20.77 (-0.88%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIK)Realized 20D OHLCV Swing Band: ±7.9%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY ANIK SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($4.4M FCF) & 56.6% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (23% of score)
20D Institutional Volume Accumulation (±7.9% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)
Dilution Drag (+1.36% YoY Shares) & executive Form 4 sales trim 13 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$20.53-0.4% Next Q
45
Q2 (-2Q)Grade D$20.44+4.5% Next Q
48
Q3 (-1Q)Grade C-$21.35-1.9% Next Q
50
CurrentGrade D+$20.95-0.9% Hist 90D α
53
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ANIK Turnaround Squeeze
While ANIK currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.66) and Max Pain ($22.00) forces dealer call-delta covering toward $24.17.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANIK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ANIK Stock dropped -3.85% Today — RQD Quant Desk Flash
Anika Therapeutics Inc. (ANIK) dropped -3.85% to $20.95, trading at 86% of its 52-week range ($9.01 – $22.88). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 86% of its 52-week range ($9.01 – $22.88) with RSI-14 at 51.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.9% around $20.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 56.6% gross margin and $4.4M annual free cash flow.
Live ANIK Headlines & Catalysts
MARKET WIREGlobeNewswire • 18h ago
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026GlobeNewswire report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 21h ago
Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Understanding Momentum Shifts in (ANIK)Stock Traders Daily report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Amylyx Pharmaceuticals, Inc. (AMLX) Seasonal Returns ChartYahoo! Finance Canada report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 38d ago
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
MARKET WIREYahoo Finance • 38d ago
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyMRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
MARKET WIREYahoo Finance • 40d ago
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyAmgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
MARKET WIREYahoo Finance • 42d ago
NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
MARKET WIREYahoo Finance • 45d ago
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsPuma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANIK)
- ✓Walkthrough of ANIK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ANIK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.99%📐 WEDGE COMPRESSION COIL
2026-11-03O $21.79H $21.79L $20.95C $20.95VOL 66.7K
RES: $21.80SUP: $19.40SMA50: $20.66SMA200: $16.19
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ANIK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ANIK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ANIK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANIK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIK)
Health Care Rank #236 of 1016
⚔️ INFU vs ANIK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ANIK vs. INFU, TMCI, OSUR, PROF)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Anika Therapeutics Inc. (ANIK) ranks #236 by composite RQD confidence (53/100, grade D+) and #524 by equity capitalization ($280.4M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with ANIK at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANIK
ACTIVE
Anika Therapeutics Inc. | D+ | 53/100 | — | 56.6% | -10.2% | -3.85% | $280.4M | Benchmark Subject |
| INFU InfuSystems Holdings Inc. | B+ | 77/100 | 43.4x | 56.0% | 12.8% | -2.63% | $280.2M | /infu-vs-anik → |
| TMCI Treace Medical Concepts Inc. | D- | 36/100 | — | 79.8% | -32.4% | -12.45% | $288.1M | /tmci-vs-anik → |
| OSUR OraSure Technologies Inc. | E | 31/100 | — | 41.9% | -35.0% | -3.43% | $271.7M | /osur-vs-anik → |
| PROF Profound Medical Corp. | D- | 40/100 | — | 70.8% | -35.0% | +12.12% | $240.0M | /prof-vs-anik → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000898437In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported GAAP revenue of $112.8M (-5.9% vs. FY2024 revenue of $119.9M , and -6.6% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of $11.2M, and free cash flow of $4.4M (+287.1% YoY). On the balance sheet, ANIK closed FY2025 with $190.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $112.8M | -$11.0M | $11.2M | $4.4M | $190.3M | — |
| FY2024 (FY) | 2024-12-31 | $119.9M | -$56.0M | $5.4M | -$2.3M | $202.7M | — |
| FY2023 (FY) | 2023-12-31 | $120.8M | -$83.0M | -$1.8M | -$1.8M | — | — |
3. ANIK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $20.95 (-3.85% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #236 in composite RQD confidence.
How does ANIK compare to INFU and TMCI in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ANIK?
Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ANIK trading relative to its 50-day, 200-day, and 52-week technical levels?
ANIK last traded at $20.95 (-3.85% on volume of 66,709 shares), positioning the stock +1.40% above its 50-day simple moving average ($20.66) and +29.40% above its 200-day simple moving average ($16.19). Across its 52-week range of $9.01 to $22.88, ANIK sits at the 86.1% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($19.29 to $22.61).
ANIK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ANIK stock moving today?
Why ANIK Stock dropped -3.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 53/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ANIK — Anika Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, ANIK scores 55 out of 100, a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine 12/20 (ROIC -10.2%; FCF yield 1.5%); Whale 13F Flow 14/20 (institutional accumulation and options positioning); Insider Conviction 7/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 11/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 11/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor evaluating the stock today, the weakest pillar is insider conviction (7/20), followed by the cash engine and balance sheet (both 11–12/20). The upside case rests mainly on the institutional flow pillar (14/20) and a balance sheet that the rating describes as moderately sound (Altman Z 2.5, Piotroski F 6/9). The valuation tradeoff is that the cash engine pillar reflects a negative ROIC and a thin 1.5% FCF yield, so the current price is not supported by demonstrated returns on capital in the provided data. The rating's verdict is a trim-oriented signal, meaning the aggregated data leans negative. This is an analytical summary, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $112.8M | $-11.1M | $-11.0M | N/A | $4.4M | $57.5M | N/A |
| FY 2024 | $119.9M | $-5.1M | $-56.0M | N/A | $-2.3M | $55.6M | N/A |
| FY 2023 | $120.8M | $0.8M | $-83.0M | N/A | $-1.8M | N/A | N/A |
Per the SEC financials, revenue declined from $120.8M (FY 2023) to $112.8M (FY 2025), and the company reported net losses in all three periods. Per the Market Data section, operating margin and net margin are each -9.8% and ROIC is -10.2%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.5. FY 2025 free cash flow was positive at $4.4M, while FY 2024 was negative.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the near-term catalyst is the scheduled release of third-quarter 2026 financial results on Friday, November 6, 2026. A TradingView item cites a Q3'26 revenue estimate of 29.44M USD, which is a headline figure only. The remaining items are a Yahoo Finance seasonal chart for Lifecore Biomedical (LFCR), a Stock Traders Daily momentum piece, and a Yahoo Finance seasonal chart for Amylyx Pharmaceuticals (AMLX). These items are labeled as market wire content and do not provide company-specific fundamental data. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.
Open Questions
- What are the actual P/E, forward P/E, EV/EBITDA, and EPS figures, given that the source data lists them as unavailable?
- What drove the FY 2024 net loss of $-56.0M and the FY 2023 net loss of $-83.0M, and are these one-time or recurring?
- What is the debt balance, since the source data lists debt as N/A for every period?
- Which products and customers generate the $112.8M of FY 2025 revenue, and what is the revenue trend outlook?
- What were the specific institutional and insider transactions behind the 14/20 and 7/20 pillar scores?
ANIK Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Anika Therapeutics Inc. (ANIK) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 15h ago
ANIK Q3'26 Earnings: revenue estimate is 29.44M USD TradingView report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 18h ago
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026 GlobeNewswire report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago
Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Understanding Momentum Shifts in (ANIK) Stock Traders Daily report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Amylyx Pharmaceuticals, Inc. (AMLX) Seasonal Returns Chart Yahoo! Finance Canada report covering Anika Therapeutics Inc. (ANIK) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 38d ago
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year? Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
🟡 MARKET WIRE Yahoo Finance • 38d ago
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
🟡 MARKET WIRE Yahoo Finance • 40d ago
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ANIK Bull vs. Bear Conversation Board — What's Your Call at $20.95?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANIK 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $23.53 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ANIK (D+ • RQD 55/100) a Buy at $21.79?
Welcome to the ANIK (Anika Therapeutics Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $17.00 (-22.0%)
Spot @ $21.79 Pump the brakes on ANIK — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ANIK, but look at what you are paying: current EV/EBITDA multiples with 56.6% gross margins. Unless Anika Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $26.15 (+20.0%)
Spot @ $21.79 ANIK cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ANIK, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $21.79 (52-wk range $9.01 - $22.88), any beat on forward guidance forces shorts and underweight funds to chase.